CINCINNATI--(BUSINESS WIRE)--Mar. 7, 2018--
Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company
focused on advancing first-in-class treatments for ocular diseases,
today announced that its fourth quarter and full year 2017 financial
results will be released before the market opens on Tuesday, March 13,
2018. Following the release, the Company will host a live conference
call and webcast at 8:30 a.m. Eastern Time to discuss the Company’s
financial results and provide a general business update.
The live webcast and a replay may be accessed by visiting Aerpio's
website at http://ir.aerpio.com/.
Please connect to the Company's website at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call (877)
216-7943 (U.S.) or (417) 629-5054 (international) to listen to the live
conference call. The conference ID number for the live call is 9278906.
Please dial in approximately 10 minutes prior to the call. Telephone
replay will be available approximately two hours after the call. To
access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406
(international). The conference ID number for the replay is 9278906.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB‐9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy. For more information please
View source version on businesswire.com: http://www.businesswire.com/news/home/20180307005409/en/
Source: Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc.
Michael Rogers, CFO,